PCSK9 inhibitors in clinical practice: Novel directions and new experiences

Baigent, 2005, Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1 Giugliano, 2017, Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol: A Prespecified Analysis of the IMPROVE-IT Trial, JAMA Cardiol, 2, 547, 10.1001/jamacardio.2017.0083 Kotseva, 2019, Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry, Eur J Prev Cardiol, 26, 824, 10.1177/2047487318825350 De Backer, 2015, EUROASPIRE Investigators. Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology, Atherosclerosis, 241, 169, 10.1016/j.atherosclerosis.2015.04.809 Rallidis, 2016, Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins, Atherosclerosis, 249, 17, 10.1016/j.atherosclerosis.2016.03.023 Stroes, 2015, Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management, Eur Heart J, 36, 1012, 10.1093/eurheartj/ehv043 Sabatine, 2017, FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, N Engl J Med, 376, 1713, 10.1056/NEJMoa1615664 Schwartz, 2018, ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome, N Engl J Med, 379, 2097, 10.1056/NEJMoa1801174 Landmesser, 2017, Eur Heart J, 38, 2245 Orringer, 2017, Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association, J Clin Lipidol, 11, 880, 10.1016/j.jacl.2017.05.001 Hlatky, 2017, PCSK9 Inhibitors: Economics and Policy, J Am Coll Cardiol, 70, 2677, 10.1016/j.jacc.2017.10.001 Galema-Boers, 2017, Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience, Clin Lipidol, 11, 674, 10.1016/j.jacl.2017.02.014 Stoekenbroek, 2018, PCSK9 inhibitors in clinical practice: Delivering on the promise?, Atherosclerosis, 270, 205, 10.1016/j.atherosclerosis.2017.11.027 Zafrir, 2018, Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic, Cardiovasc Ther, 36, e12439, 10.1111/1755-5922.12439 Achimastos, 2016, Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, Hormones (Athens), 15, 8, 10.1007/BF03401398 Civeira, 2004, Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia, Atherosclerosis, 173, 55, 10.1016/j.atherosclerosis.2003.11.010 Santos, 2016, Lancet Diabetes Endocrinol, 4, 850, 10.1016/S2213-8587(16)30041-9 Nissen, 2016, GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial, J Am Med Assoc, 315, 1580, 10.1001/jama.2016.3608 Urban, 2013, Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis, J Am Coll Cardiol, 62, 1401, 10.1016/j.jacc.2013.07.056 Toth, 2017, Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia, J Am Heart Assoc, 6 Perez de Isla, 2016, SAFEHEART Investigators. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up, J Am Coll Cardiol, 67, 1278, 10.1016/j.jacc.2016.01.008 Rizos, 2018, Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH), Atherosclerosis, 277, 308, 10.1016/j.atherosclerosis.2018.08.017 Rallidis, 2018, Eligibility for treatment with PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximum hypolipidaemic therapy, Hellenic J Cardiol, 59, 293, 10.1016/j.hjc.2017.11.004 Saeed, 2018, Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse, J Clin Lipidol, 12, 1141, 10.1016/j.jacl.2018.05.017 Bays, 2018, Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials, Cardiovasc Drugs Ther, 32, 175, 10.1007/s10557-018-6784-z